Showing results (191-200 of 273) with videos related to
Sort By:
Pageof 28
Research Square|June 17, 2024
Genome-wide association study of glucocerebrosidase activity modifiersEmma N Somerville, Lynne Krohn, Konstanin Senkevich, et al.Archives of General Psychiatry|April 7, 2004
Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trialCynthia McRae, Eva Cherin, T Gayle Yamazaki, et al.Archives of Neurology|February 16, 2006
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuationsKaren Blindauer, Ira Shoulson, David Oakes, et al.Movement Disorders : Official Journal of the Movement Disorder Society|December 23, 2021
Discussion of Research Priorities for Gait Disorders in Parkinson's DiseaseNicolaas I Bohnen, Rui M Costa, William T Dauer, et al.Movement Disorders : Official Journal of the Movement Disorder Society|December 14, 2011
Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's diseaseAndrew Lees, Stanley Fahn, Karla M Eggert, et al.Archives of Neurology|April 17, 2008
Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort methodYuanjia Wang, Lorraine N Clark, Elan D Louis, et al.Journal of Neurodevelopmental Disorders|February 3, 2015
Emerging topics in FXTASDeborah A Hall, Rachael C Birch, Mathieu Anheim, et al.Scientific Reports|August 20, 2024
Molsidomine provides neuroprotection against vincristine-induced peripheral neurotoxicity through soluble guanylyl cyclase activationIrina Utkina-Sosunova, Alessia Chiorazzi, Mariangels de Planell-Saguer, et al.Journal of Neurodevelopmental Disorders|April 9, 2015
Erratum: Emerging topics in FXTASDeborah A Hall, Rachael C Birch, Mathieu Anheim, et al.Nature Communications|May 1, 2025
Synaptic vesicle-omics in mice captures signatures of aging and synucleinopathyVirginia Gao, Julita Chlebowicz, Karlton Gaskin, et al.Pageof 28